Retatrutide: The Triple Agonist That Lost 28.7% Body Weight in Phase 3

On December 11, 2025, Eli Lilly announced the results of TRIUMPH-4, the first Phase 3 trial for retatrutide. The headline number stopped the pharmaceutical world: patients on the highest dose lost an average of 28.7% of their body weight—71.2 pounds—in 68 weeks. That’s the highest weight loss ever recorded in a Phase 3 clinical trial for any obesity medication.

Retatrutide represents the next evolutionary leap in GLP-1 science. While semaglutide (Wegovy) targets the GLP-1 receptor alone and tirzepatide (Zepbound) targets both GLP-1 and GIP receptors, retatrutide is the first “triple agonist”—it activates GLP-1, GIP, and glucagon receptors simultaneously. The addition of glucagon agonism is what makes it different, and early data suggests that difference matters enormously.

TRIUMPH-4 Results: The Numbers

Beyond weight loss, retatrutide showed clinically meaningful improvements in cardiovascular risk markers. Non-HDL cholesterol, triglycerides, and high-sensitivity C-reactive protein all dropped significantly. One in eight patients on the 12 mg dose reported complete freedom from knee pain—compared to 4.2% on placebo.

How Retatrutide Compares to Current Medications

The Safety Signal: Dysesthesia

TRIUMPH-4 revealed a new safety signal that wasn’t present in Phase 2 testing. Dysesthesia—an abnormal sensation of touch where normal stimuli feel unusual or uncomfortable—occurred in 8.8% of patients on the 9 mg dose and 20.9% on the 12 mg dose, compared to 0.7% on placebo. These events were generally described as mild and rarely led to discontinuation, but the dose-dependent pattern is notable.

The standard GI side effects seen with all GLP-1 class drugs were present as expected: nausea, diarrhea, constipation, vomiting, and decreased appetite occurred more frequently with retatrutide than placebo. Analysts will be watching closely for the dysesthesia signal in the remaining seven Phase 3 trials reporting throughout 2026.

The TRIUMPH Phase 3 Program: What’s Coming in 2026

TRIUMPH-4 was just the beginning. Eli Lilly has seven additional Phase 3 trials expected to report results in 2026, covering weight management in broader populations (TRIUMPH-1 and TRIUMPH-2), patients with cardiovascular disease (TRIUMPH-3), obstructive sleep apnea, chronic low back pain, metabolic liver disease (MASH), and cardiometabolic outcomes. The program has enrolled more than 5,800 participants across all trials.

In March 2026, Lilly announced positive results from TRANSCEND-T2D-1, the first Phase 3 trial evaluating retatrutide for type 2 diabetes. Patients achieved up to 2.0% HbA1c reduction and nearly 17% weight loss at just 40 weeks, with no plateau observed. This positions retatrutide for potential approval in both obesity and diabetes.

Citi analysts have noted that TRIUMPH-1, with its 80-week duration, could potentially show weight loss exceeding 30%—a threshold never before achieved in any obesity drug trial. GlobalData projects retatrutide sales could reach $15.6 billion by 2031 if approved.

When Will Retatrutide Be Available?

Based on current timelines, the expected trajectory is: all remaining Phase 3 trials report results throughout 2026, Eli Lilly submits a New Drug Application to the FDA in late 2026 or early 2027, the standard FDA review takes 10–12 months, and commercial launch occurs around late 2027 or early 2028. This assumes all trials succeed and no major safety issues emerge.

Can Retatrutide Be Compounded?

This is a critical question for the compounding industry. Retatrutide is a peptide, which under current FDA classification means it could potentially be compounded by 503A and 503B pharmacies if certain conditions are met. However, Eli Lilly has been aggressive in protecting its GLP-1 intellectual property—the company filed 132 federal complaints against semaglutide compounders in 2025 alone. It’s reasonable to expect similar enforcement action if compounders attempt to produce retatrutide.

For patients currently using compounded semaglutide or tirzepatide, retatrutide represents the next horizon of GLP-1 therapy. The 28.7% weight loss figure is remarkable, and the additional cardiovascular and metabolic benefits suggest this is more than just a weight loss drug. The 2026 data readouts will determine whether retatrutide lives up to its unprecedented potential.